Integrin alpha V beta 3 targeted dendrimer‐rapamycin conjugate reduces fibroblast‐mediated prostate tumor progression and metastasis by Hill, Elliott E. et al.
Au
tho
r M
an
us
cri
pt
This article is protected by copyright. All rights reserved. 
Research Article 
Integrin Alpha V Beta 3 Targeted Dendrimer-Rapamycin Conjugate 
Reduces Fibroblast-Mediated Prostate Tumor Progression and Metastasis1 
 
Elliott E. Hill, 1,* * Jin Koo Kim 0000-0003-4268-1118, 1,2,* * Younghun Jung, 4 Chris K. 
Neeley, 5 Kenneth J. Pienta, 5 Russell S. Taichman, 4 Jacques E. Nor, 6 James R. Baker, 
Jr., 7 and  
Paul H. Krebsbach 1,2,3* 
1 Department of Biologic and Materials Sciences, University of Michigan School of 
Dentistry, Ann Arbor, MI, USA 
2 Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA  
3 Section of Periodontics, University of California, Los Angeles School of Dentistry, Los 
Angeles, CA, USA 
4 Department of Periodontics and Oral Medicine, University of Michigan School of 
Dentistry, Ann Arbor, MI, USA 
5 Department of Urology, The James Buchanan Brady Urological Institute, Johns 
Hopkins School of Medicine, Baltimore, MD, USA 
6 Department of Cariology, Restorative Sciences and Endodontics, University of 
Michigan School of Dentistry, Ann Arbor, MI, USA 
7 Department of Internal Medicine, Pathology and Nanotechnology, University of 
Michigan, Ann Arbor, MI, USA 
 
*
 Correspondence to: Paul H. Krebsbach, Section of Periodontics, University of 
California, Los Angeles School of Dentistry, Los Angeles, CA, USA.  
E-mail: pkrebsbach@dentistry.ucla.edu 
**
 Two authors contributed equally to this work. 
Running head: G5-rapamycin reduces PCa progression 
KEY WORDS: DENDRIMER; CYCLIC RGD PEPTIDE; RAPAMYCIN; VEGF; 
PROSTATE CANCER; FIBROBLAST 
Total number of text figures: 5 
 
1
 This is the author manuscript accepted for publication and has undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as 
doi:10.1002/jcb.26727 
 
Au
tho
r M
an
us
cri
pt
Contract grant sponsor:  
  National Cancer Institute; CA093900, CA163124.  
  Department of Defense; W81XW-15-1-0413, W81XWH-14-1-0403.  
  Prostate Cancer Foundation. 
Au
tho
r M
an
us
cri
pt
Abstract 
Therapeutic strategies targeting both cancer cells and associated cells in the tumor 
microenvironment offer significant promise in cancer therapy. We previously reported 
that generation 5 (G5) dendrimers conjugated with cyclic-RGD peptides target cells 
expressing integrin alpha V beta 3. In this study, we report a novel dendrimer conjugate 
modified to deliver the mammalian target of rapamycin (mTOR) inhibitor, rapamycin. In 
vitro analyses demonstrated that this drug conjugate, G5-FI-RGD-rapamycin, binds to 
prostate cancer (PCa) cells and fibroblasts to inhibit mTOR signaling and VEGF 
expression. In addition, G5-FI-RGD-rapamycin inhibits mTOR signaling in cancer cells 
more efficiently under proinflammatory condition compared to free rapamycin. In vivo 
studies established that G5-FI-RGD-rapamycin significantly inhibits fibroblast-mediated 
PCa progression and metastasis. Thus, our results suggest the potential of new 
rapamycin-conjugated multifunctional nanoparticles for PCa therapy.   
 
 
 
 
In the progression of prostate cancer, metastasis often represents a fatal step, with 90% of 
deaths resulting from metastases rather than from the primary tumor [Sporn, 1996; Tse 
and Kalluri, 2007]. This finding has generated great interest in developing targeted cancer 
therapeutics. Effective therapies would target both the metastatic cells and cells of the 
microenvironment that permit their survival [Bhowmick et al., 2004; Bussard et al., 2008; 
Canon et al., 2007; Dai et al., 2017; Doehn et al., 2009]. Angiogenesis is an essential 
factor in tumor cell growth and survival, and the correlation between neovascularization, 
micro-vessel density, and metastatic carcinoma [Folkman, 1992; Weidner et al., 1992] 
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has been confirmed as an important parameter in tumor progression [Dai et al., 2004; 
Kaplan et al., 2005]. Several studies demonstrate that growth factors in the tumor 
microenvironment and the local host tissues are active participants in this process [Hattori 
et al., 2002; Liotta and Kohn, 2001]. One such growth factor, vascular endothelial growth 
factor (VEGF), is known to enhance the tumor angiogenic potential and has emerged as a 
target for anticancer therapy with several drugs currently in clinical trials [Decaussin et 
al., 1999; Kuhn et al., 2007]. Taken together, these findings have led to an intense interest 
in identifying innovative methods to modulate both the source and the impact of these 
angiogenic factors on tumor progression [Dai et al., 2004; Decaussin et al., 1999; Ito et 
al., 2007; Kaplan et al., 2005; Yang et al., 2008].  
Macrophages, infiltrating eosinophils, and fibroblasts are implicated in tumor 
progression [Gleave et al., 1991; Hwang et al., 2008; Pollard, 2008; Tuxhorn et al., 2002]. 
More recently, stromal fibroblasts, the most abundant cell type in the stroma of 
carcinomas, have been identified as a source of VEGF and other factors that promote an 
angiogenic response to neoplasms [Bhowmick et al., 2004; Hwang et al., 2008; Ito et al., 
2007; Orimo et al., 2005]. Proliferating fibroblasts, enhanced capillary density, and 
deposition of type-1 collagen and fibrin are hallmarks of a tissue stroma response to 
tumor progression and metastasis [Kalluri and Zeisberg, 2006; Kaplan et al., 2005; 
Zeisberg et al., 2007]. Recent studies illustrate that these changes are, in part, regulated 
by integrin-fibroblast interactions [Scaffidi et al., 2001]. Yet these fibroblasts have, until 
recently, been largely overlooked as targets in cancer therapy.  
The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase 
that participates in the formation of two distinct signaling complexes; mTOR complex 1 
(mTORC1), containing the regulatory-associated protein of mTOR (Raptor), and mTOR 
complex 2 (mTORC2), containing the rapamycin-insensitive companion of mTOR 
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(Rictor). mTORC1 phosphorylates ribosomal S6 Kinase (S6K) and activated S6K 
phosphorylates ribosomal protein S6 (rpS6), stimulating protein synthesis, cell growth, 
and cell proliferation. In contrast, mTORC2 phosphorylates Akt and PKCα, promoting 
cell survival and cytoskeleton reorganization. Rapamycin, a specific inhibitor of mTOR, 
directly binds to mTORC1 and inhibits its activity. However, mTORC2 is insensitive to 
rapamycin, although prolonged treatment can inhibit mTORC2 in many cell types 
[Laplante and Sabatini, 2012].  
Integrins play a key role in cell adhesion to RGD motifs within proteins of the 
extracellular matrix (ECM), triggering signal transduction mechanisms involved in stem 
cell self-renewal [Krebsbach and Villa-Diaz, 2017; Villa-Diaz et al., 2016], cell 
proliferation and survival [Hynes, 2002], and tumor metastasis [Kwakwa and Sterling, 
2017]. We previously reported that generation 5 dendrimers can be conjugated with 
cyclic-RGD peptides that target and bind with specificity to cells that express high levels 
of the receptors for integrin alpha V beta 3 [Hill et al., 2007; Rameshwer Shukla, 2008]. 
Here, we report the synthesis of a novel dendrimer conjugate with rapamycin, G5-FI-
RGD-rapamycin. Furthermore, we report that G5-FI-RGD-rapamycin binds to prostate 
cancer cells as well as the fibroblasts that support them to suppress tumor progression. 
We also demonstrate that G5-FI-RGD-rapamycin blocks the mTOR signaling pathway 
that modulates VEGF expression and subsequently impedes metastatic tumor progression. 
 
MATERIALS AND METHODS 
 
DENDRIMER SYNTHESIS 
Commercially available generation 5 (G5) poly amido amine (PAMAM) dendrimer 
(Dendritech, Midland, MI) was prepared and analyzed at the Michigan Nanotechnology 
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Institute of Medicine and Biological Sciences as previously described. Briefly, G5 amine 
terminated dendrimer was partially neutralized via acetylation (0.01 mmol G5 amine 
dendrimer and 0.085 mmol triethy amine/0.074 mmol acetic anhydride). The reaction 
was run overnight in anhydrous MeOH at room temperature. Subsequently, the reaction 
mixture was purified via dialysis (10,000 MWCO) and the average number of acetyl 
groups (75) was determined via a 1HNMR calibration curve. G5Ac (75) was further 
modified via 1:3 molar addition of fluorescein isothiocyanate (FI) in DMSO overnight. 
Free FI dye was removed by an elution column (G25 sephadex). An active ester was 
prepared by reacting G5Ac (75) with an excess of gluaric anhydride, repeating 
purification via dialysis then reacting the conjugate with an excess of 1-[3-
(Dimethylamino) propyl]-3-ethylcarbodiimide methiodide (EDC) and again repeating 
dialysis. Finally, a commercially available αVβ3 specific cyclic arginine-glycine-aspartic 
acid (RGD) peptide (cRGDyK, Peptides International, Louisville, KY) was added in a 
5:1 molar ratio to G5Ac (75)-FI ester and purification steps were repeated. The 
esterfication steps were repeated, then commercially available rapamycin (Sigma-Aldrich, 
St. Louis, MO) was added in a 8:1 ratio to the G5Ac (75)-FI-RGD conjugate and the final 
compound (G5-FI-RGD-rapamycin) was purified via dialysis. 
    
CELL CULTURE 
 Primary bone marrow-derived stromal fibroblasts were collected from human or mouse 
bone marrow [Jung et al., 2013; Wang et al., 2010]. Primary fibroblasts and cancer cell 
lines (PC3, C4-2B, MDA-MB-231, and HeLa; American Type Culture Collection) were 
grown in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Carsbad, CA) 
supplemented with 10% FBS and 1% penicillin/streptomycin. Human dermal 
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microvascular endothelial cells (HDMEC; Cambrex, Walkersville, MD) were cultured in 
endothelial growth medium-2 for microvascular cells (EGM2-MV; Cambrex).  
 
FLOW CYTOMETRY 
Human fibroblast cells were treated with 200 nM G5-FI-RGD-rapamycin for 6 h 
with/without pre-treatment with 1 µM free RGD peptide. Cells were then disassociated 
from the culture dish by trypsinization, washed in PBS and analyzed via flow cytometry 
for mean fluorescent intensity (Beckman Coulter, Fullerton CA). 
 
IMMUNOFLUORESCENCE 
Approximately 5 x 105 human fibroblastswere seeded onto six well culture dishes (Matek 
Corp., Ashland MA) and cultured in 3 ml of medium for at least 24 h before the initiation 
of the experimental conditions. Samples were treated with G5-FI-RGD-rapamycin (200 
nM) for 6 h with/without pre-treatment with 1 µM free RGD peptide and examined for 
G5-conjugate uptake using a Carl Ziess confocal microscope. 
 
WESTERN BLOT ANALYSIS 
Whole cell lysates were prepared from cells, separated on 10% SDS-polyacrylamide gel 
and transferred to PVDF membrane. The membranes were incubated with 5% milk for 1 
h and incubated with primary antibodies overnight at 4oC. Primary antibodies used were 
as follows: VEGF (1:1000; Santa Cruz, Santa Cruz, CA), FGF-2 (1:1000; Santa Cruz), 
phospho-S6K1 (Thr389) (1:1000; Cell Signaling, Danvers, MA), S6K1 (1:1000; Cell 
Signaling), phospho-S6 (Ser 240/244) (1:4000; Cell Signaling), and S6 (1:4000; Cell 
Signaling). Blots were incubated with peroxidase-coupled secondary antibodies 
(Promega, Madison, WI) for 1 h, and protein expression was detected with SuperSignal 
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West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL). Membranes 
were reprobed with anti-GAPDH antibody (Chemicon, Temecula, CA) to control for 
equal loading. 
 
ELISA 
HDMEC and human or mouse fibroblasts were treated with 200 nM G5-FI-RGD-
rapamycin for 24 h. Supernatants of cell cultures were collected and centrifuged to 
eliminate cell debris. VEGF expression was determined by a human VEGF Quantikine 
ELISA kit (R&D systems, Minneaplis, MN) following the manufacturer’s instructions. 
The fluorescence was quantified via a TECAN microplate reader (TECAN US, Durham, 
NC).  
 
IN VIVO TUMOR GROWTH AND ANGIOGENESIS ASSAY 
PC3 cells (1.5 x 106) with or without pretreatment with G5-FI-RGD-rapamycin (200 nM) 
for 12 h, were implanted in the flank of SCID mice. Subsequently, human or mouse 
fibroblasts (1.5 x 106) with/without pretreatment with G5-FI-RGD-rapamycin (200 nM) 
for 12 h were co-implanted with PC3 cells. Tumor volume was calculated twice a week 
for the duration of the experiment using the formula: Volume (mm3) = length x 
(width)2/2.  
      After three weeks, mice were euthanized and tumors were harvested, fixed, and 
processed for standard immunohistochemistry. Histological sections were incubated in 
antigen retrieval solution for 30 min at 900C, followed by incubation with polyclonal 
anti-human factor VIII antibody (Lab Vision, Fremont, CA) over night at 40C [Nor et al., 
1999]. The number of blood vessels in six random fields was counted per experimental 
condition under light microscope. The care and treatment of experimental animals was in 
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accordance with University of Michigan institutional guidelines. At least three 
independent experiments were performed to verify reproducibility of results. 
 
IN VIVO METASTASIS ASSAY 
PC3 cells that were stably transfected with luciferase (PC3luc) cells were injected into the 
left cardiac ventricle of SCID mice. Four experimental groups were established; group 
one received 1 mg/kg G5-FI-RGD-rapamycin treatment 48 h before inoculation with 
tumor cells, group two received treatment at the time of tumor cell inoculation, group 
three received treatment 48 h after tumor cell inoculation and group four was inoculated 
with tumor cells and afterwards untreated. G5-FI-RGD-rapamycin was intraperitoneally 
treated 2 times per week for four weeks. At 1, 2, 3 and 4 week time points, 
bioluminescence imaging was performed to follow prostate cancer-derived bone 
metastases as a primary outcome. Immediately prior to each imaging session, the mice 
were injected intraperitoneally with luciferin (100 µl at 40 mg/ml in PBS). Mice were 
then anesthetized with 1.5% isoflurane/air, using the Xenogen IVIS (Caliper Life Science, 
Hopkinton MA. USA) cryogenically cooled imaging system. Bioluminescence generated 
by the luciferin/luciferase reaction was used for quantification of cancer growth using the 
LivingImage software (Caliper Life Science, Hopkinton MA. USA). Signal intensity was 
quantified as the sum of all detected photons during a 1-minute luminescent integration 
time. 
 
STATISTICAL ANALYSES  
Results are presented as mean ± standard deviation (SD) or standard error (SE) of mean. 
Significance of the difference between two measurements was determined by unpaired 
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the Student’s t-test, and multiple comparisons were evaluated by the Newman-Keuls 
multiple comparison test. Values of p < 0.05 were considered significant. 
 
RESULTS 
 
SYNTHESIS OF G5-FI-RGD-RAPAMYCIN DENDRIMER  
To eliminate non-specific binding, generation 5 (G5) dendrimers were partially surface 
modified with acetic anhydride (75) and subsequently conjugated with fluorescein 
isothiocyanate (FI), RGD, and rapamycin (Fig. 1A). Gel-permeation chromatography 
(GPC) was used to confirm dendrimer conjugate homogeneity (Fig. 1B). Data generated 
via a GPC eluogram demonstrated a monodispersed conjugate population with a poly-
dispersity index (PDI) of 1.04. To demonstrate that G5 dendrimers functionalized with 
RGD and rapamycin bind to human bone marrow-derived fibroblasts, the cells were 
treated with 200 nM G5-FI-RGD-rapamycin for 6 h. Confocal microscopy analysis 
revealed robust binding and internalization of the conjugate after treatment with 200 nM 
G5-FI-RGD-rapamycin (Fig. 1C). The observed binding was inhibited when the cells 
were pre-incubated with 1 µM of free RGD peptide for 30 min prior to G5-FI-RGD-
rapamycin treatments, confirming specificity (Fig. 1C). Flow cytometry analysis 
confirmed dendrimer binding to fibroblasts as indicated by an increase in fluorescent 
intensity relative to untreated fibroblasts (Fig. 1D). The binding was also blocked when 
the fibroblasts were pre-incubated with 1 µM of free RGD peptide for 30 min prior to 
G5-FI-RGD-rapamycin treatments (Fig. 1D). Together, these results strongly indicate the 
successful conjugation of a multifunctional G5-FI-RGD-rapamycin dendrimer that 
specifically targeted cells that express integrin αVβ3. 
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G5-FI-RGD-RAPAMYCIN INHIBITS mTOR SIGNALING IN FIBROBLASTS 
AND CANCER CELLS 
Rapamycin alters protein translation by inhibiting mammalian target of rapamycin 
complex 1 (mTORC1) signaling [Guertin and Sabatini, 2007; Martin et al., 2004; 
Schmelzle and Hall, 2000]. Therefore, G5-FI-RGD-rapamycin was tested as an mTORC1 
inhibitor. Western blot analysis revealed that treatment with G5-FI-RGD-rapamycin (0.5 
nM, 1 nM, 10 nM or 50 nM) blocked mTORC1-mediated S6K1 phosphorylation 
(Thr389) at levels similar to free rapamycin treatments in human fibroblasts (Fig. 2A). 
G5-FI-RGD-rapamycin (20 nM and 200 nM) also strongly inhibited S6K1-mediated 
phosphorylation of ribosomal protein S6 (rpS6) at levels similar to free rapamycin 
treatments in HeLa (cervical cancer), PC3 (prostate cancer), and MDA-MB-231 (breast 
cancer) cells in normal culture conditions (Fig. 2B). Interestingly, when cancer cells were 
stimulated with with TNF-α stimulation to mimic proinflammatory conditions, the 
sensitivity to free rapamycin (both 20 nM and 200 nM) was significantly reduced (Fig. 
2B). Critically, in TNF-α stimulated PC3 cells treated with 20 nM or 200 nM G5-FI-
RGD-rapamycin and in TNF-α stimulated HeLa and MDA-MB-231 cells treated with 
200 nM G5-FI-RGD-rapamycin, sensitivity to rapamycin was sustained (Fig. 2B). These 
results suggest that G5-FI-RGD-rapamycin significantly inhibits mTOR signaling in 
cancer cells under proinflammatory conditions more efficiently than unconjugated 
rapamycin. 
 
G5-FI-RGD-RAPAMYCIN REDUCES VEGF EXPRESSION IN RAPAMYCIN 
SENSITIVE CELLS  
Growing evidence demonstrates that two key regulators of angiogenesis, vascular 
endothelial growth factor (VEGF), and fibroblast growth factor (FGF) are up-regulated in 
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both advanced tumor cells and their reactive stromal fibroblast cells [Ferrara and Kerbel, 
2005; Fukumura et al., 1998; Nor and Polverini, 1999]. To determine how VEGF and 
FGF-2 expression from the cancer cells or fibroblast cells respond to G5-FI-RGD-
rapamycin, rapamycin sensitive cells (PC3, C42B, and human fibroblast) and rapamycin 
insensitive cells (HDMEC, MDA-MB-231, and HeLa) [Sarbassov et al., 2006] were 
treated with 200 nM G5-FI-RGD-rapamycin for 24 h and VEGF and FGF-2 expression 
were analyzed by Western blotting. Under these conditions, G5-FI-RGD-rapamycin 
inhibited VEGF expression in rapamycin-sensitive prostate cancer cells, PC3, C4-2B, and 
human fibroblast cells (Fig. 3A), but there was no impact on the rapamycin-insensitive 
cells, HDMEC, MDA-MB-231, and HeLa cells (Fig. 3B). Distinctively, FGF2 expression 
was not altered by G5-FI-RGD-rapamycin in both rapamycin sensitive cells (Fig. 3A) 
and rapamycin-insensitive cells (Fig. 3B).  
To investigate the effects of prostate cancer cell-secreted factors on VEGF 
secretion in human fibroblasts, cells were cultured for 24 h with conditioned medium 
from PC3 or G5-FI-RGD-rapamycin (200 nM) treated PC3 and analyzed by Western 
blotting for detection of VEGF and FGF2. Results demonstrated that treatment with 
conditioned medium from PC3 cells increased VEGF protein levels from human 
fibroblasts and that conditioned medium from G5-FI-RGD-rapamycin treated PC3 did 
not increase VEGF protein levels from human fibroblasts (Fig. 3C). HDMEC and human 
or mouse fibroblast cells were treated with 200 nM G5-FL-RGD-rapamycin for 24 h and 
culture supernatants were assayed by ELISA for detection of secreted VEGF. Results 
indicated a 50% reduction in VEGF secretion from both human and mouse fibroblasts 
following G5-FI-RGD-rapamycin treatment (Fig. 3D). Taken together, these results 
suggest that VEGF secretion from fibroblasts is influenced by tumor-secreted factors and 
that G5-FI-RGD-rapamycin treatment inhibits this effect. 
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G5-RGD-RAPAMYCIN INHIBITS FIBROBLAST MEDIATED PCa 
PROGRESSION IN VIVO 
Next, we determined how fibroblasts play a role in tumor progression in vivo, and the 
extent to which this role is dependent of mTOR signaling. PC3 cells were pretreated with 
or without 200 nM G5-FI-RGD-rapamycin for 12 h and were injected with either human 
or mouse fibroblasts into the flanks of SCID mice. In parallel experiments, human or 
mouse fibroblasts were pre-treated with 200 nM G5-RGD-rapamycin for 12 h prior to co-
implantation with PC3 cells. The volume of these tumor xenografts was monitored for 22 
days. Treating PC3 cells with 200 nM G5-FL-RGD-rapamycin did not affect tumor 
progression when compared to PC3 without treatment (Fig. 4A). PC3 cells co-implanted 
with either human or mouse fibroblasts demonstrated a fourfold increase in tumor growth 
compared to PC3 cells alone (Fig. 4A). Pre-treating either the human or mouse 
fibroblasts with G5-FI-RGD-rapamycin prior to co-implantation did not affect the 
viability of fibroblasts but reduced fibroblast-mediated tumor growth twofold (Fig. 4A). 
These results suggest that fibroblasts enhance tumor progression and indicate that this 
enhancement is mTOR signaling dependent. 
Because enhanced capillary density is a hallmark of tissue stroma reacting to and 
promoting tumor progression toward metastasis [Kalluri and Zeisberg, 2006; Kaplan et 
al., 2005; Zeisberg et al., 2007], we analyzed the effects of treatment with G5-FL-RGD-
rapamycin on blood vessel density in tumor xenografts in SCID mice. Xenografts from 
PC3 cells with or without co-implantation with fibroblasts were collected, sectioned, and 
stained for factor VIII, an essential clotting factor found in blood vessels. In parallel 
experiments, xenografts from tumors formed from PC3 cell co-implanted with fibroblasts 
pre-treated with G5-FL-RGD-rapamycin (200 nM) were also sectioned and stained for 
factor VIII. Blood vessel density of these samples were subsequently quantified. Results 
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revealed that co-implanting PC3 cells with human or mouse fibroblasts increases blood 
vessel density showing both increased size and number of blood vessels (Fig. 4B and C). 
The density was significantly reduced when fibroblasts were treated with G5-FL-RGD-
rapamycin before implantation (Fig. 4B and C). 
 
G5-RGD-RAPAMYCIN INHIBITS PCa METASTASIS IN VIVO 
We extended our in vivo studies to include G5-FI-RGD-rapamycin. Luciferase tagged 
PC3 cells were injected into the left ventricle of the hearts of SCID mice. These mice 
were then treated with 1 mg/kg G5-FL-RGD-rapamycin under one of the following 
conditions: Group 1 served as a control in which the animals were untreated to the PC3 
cell injections. Group 2 animals were treated with the G5 conjugates 48 h prior to the 
PC3 cell injections. Group 3 animals were treated with the G5 conjugates at the time of 
PC3 cell injections. Group 4 animals were treated with the G5 conjugates 48 h after PC3 
cell injections. Thereafter, the G5-FI-RGD-rapamycin was intraperitoneally treated 2 
times per week for four weeks in group 2, group 3, and group 4. Results were compared 
to controls that were injected with PC3 cells but not treated with G5 conjugates. 
Bioluminescence data showed that treatment with G5-FL-RGD-rapamycin significantly 
reduced tumor burden in the post-treatment group (Group 4) and dramatically reduced 
tumor burden in the pre-treatment group (Group 2) and immediate-treatment group 
(Group 3) compared to controls (Group 1) (Fig. 5). Taken together, these data suggest 
G5-FI-RGD-rapamycin is effective in modulating prostate tumor progression and 
metastasis.  
 
DISCUSSION 
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Groundbreaking research using dendritic nano-polymers for the targeted delivery of 
therapeutic drugs has demonstrated promising therapeutic potential. Dendritic polymers 
are currently being evaluated for many in vivo biological applications including scaffolds 
used in tissue engineering, imaging (magnetic resonance, near-infrared, and positron 
emission), boron-neutron capture therapy, and cancer therapy [Lee et al., 2005; Paleos et 
al., 2007; Pan et al., 2014; Tomalia et al., 2007] and several first generation nano-carriers 
are now approved by the FDA [Ellerhorst et al., 1999; Fassas and Anagnostopoulos, 
2005; Green et al., 2006]. However, the development of dendritic polymers that target 
fibroblasts is just now emerging. Furthermore, using these polymers to modify specific 
cellular and molecular mechanisms by which fibroblasts modify the microenvironment 
and enhance tumor metastasis is only beginning to materialize. 
In a recent study, investigators described a novel type of fibroblast activation in 
response to a growing tumor that led to an increased production of growth factors and 
pro-inflammatory and proteolytic proteins, while at the same time cytoskeletal proteins 
were degraded [Rasanen et al., 2009]. VEGF, HGF/SF, and FGF7 mRNA levels were 
upregulated to variable degrees in tumor-activated fibroblasts. These activated cells 
caused an increase in colony unit formation of primary tumor cell lines (UT-SCC-43A 
and UT-SCC-74A). These results shed light on a study that suggested that human 
prostatic carcinoma-associated fibroblasts grown with initiated human prostatic epithelial 
cells dramatically stimulated growth and altered histology of the epithelial population 
[Olumi et al., 1999]. In addition, they are consistent with our results, which demonstrate 
that accessory fibroblasts are necessary for prostate tumor progression. We observed that 
co-implantation of PC3 with human fibroblasts exhibited a fourfold increase in tumor 
volume as compared to PC3 cells alone. In addition, treating these fibroblasts with G5-
FI-RGD-rapamycin prior to implantation resulted in a twofold reduction in tumor volume 
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and a marked reduction of blood vessel density in tumor. Together, these data support 
published reports suggesting that fibroblasts play an important role in tumor progression 
and further indicate that mTOR signaling may play an important role. Our analysis of two 
cytokines, VEGF and FGF2, known to play a role in fibroblast-mediated tumor 
progression revealed that only VEGF is upregulated in fibroblasts by conditioned 
medium from cancer cells and this increase is eliminated by G5-FI-RGD-rapamycin. 
Recent studies showed that insulin-like growth factor 2 (IGF2) secreted from cancer cells 
increases VEGF secretion from cancer-associated fibroblasts [Xu et al., 2017] and that 
mTOR promotes IGF2 expression [Dai et al., 2013; Dai et al., 2011]. Thus, IGF2 in PC3 
conditioned medium may induce VEGF expression from fibroblasts and IGF2 secretion 
from PC3 cancer cells may be inhibited by G5-FI-RGD-rapamycin. Inflammatory 
cytokines such as TNFα activate mTOR signaling and promote tumor angiogenesis via 
VEGF production [Lee et al., 2007]. In addition, TNFα increases αVβ3 integrin 
expression and migration in human cancer cells [Hou et al., 2011]. Because αVβ3 
integrin signaling activates mTOR signaling [Lee et al., 2010], it is possible that G5-FI-
RGD-rapamycin inhibit mTOR signaling more efficiently than free rapamycin by 
targeting αVβ3 under inflammatory condition. Indeed, further analysis showed that 
unlike free rapamycin, G5-FI-RGD-rapamycin retains its mTOR signaling inhibitory 
effects in the presence of TNFα. In vivo results confirmed in vitro data by showing that 
treatment with G5-FI-RGD-rapamycin reduces tumor burden and metastasis in a mouse 
model. Interestingly, published reports of free rapamycin treatment for this model do not 
reflect the efficacy we observed in reduction of tumor burden leading us to suspect that 
there is a dendrimer effect in the observed results. Further investigations are required to 
reveal what mechanisms are responsible for these observations and the results should 
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have important implications for the development of therapies for the treatment of 
metastatic prostate cancers.  
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FIGURE LEGENDS 
 
Fig. 1. Synthetic scheme and characterization of G5-FI-RGD-rapamycin. (A) Synthetic 
scheme. (B) Dendrimer homogeneity was confirmed via GPC with a poly-dispersity 
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index of 1.04. (C) Human fibroblasts (HFs) were treated with 200 nM G5-FI-RGD-
rapamycin for 6 h. Confocal images. Robust binding was observed after 6 h (left panel) 
and eliminated by pre-incubation with 1 µM free RGD peptide (right panel). Scale bars, 
50 µm. (D) Conjugate binding to HFs was confirmed via flow cytometry (left panel) and 
eliminated by pre-incubation with 1 µM free RGD peptide (right panel). 
 
Fig. 2. G5-FI-RGD-rapamycin inhibits mTOR signaling in fibroblasts and cancer cells. 
(A) G5-FI-RGD-rapamycin blocked S6K1 phosphorylation at the similar levels to free 
rapamycin treatment. Human fibroblasts were treated with the indicated concentration of 
free rapamycin or G5-FI-RGD-rapamycin for 24 h and analyzed by Western blotting with 
the indicated antibodies. (B) G5-FI-RGD-rapamycin renders cancer cells sensitive to 
rapamycin-mediated inhibition of rpS6 phosphorylation under proinflammatory condition. 
Human cancer cells were treated with the indicated concentration of free rapamycin 
(Rapa) or G5-FI-RGD-rapamycin (G5-Rapa) with/without TNF-α (20 ng/ml) for 24 h 
and analyzed by Western blotting with the indicated antibodies. Band intensity for rpS6 
phosphorylation was quantified using Image J software and normalized to rpS6. 
 
Fig. 3. G5-FI-RGD-rapamycin reduces VEGF expression in rapamycin sensitive cells. 
(A) Rapamycin sensitive cells (PC3, C42B, and human fibroblast (HF)) and (B) 
rapamycin insensitive cells (HDMEC, MDA-MB-231, and HeLa) were treated with 200 
nM G5-FI-RGD-rapamycin (G5-Rapa) for 24 h and analyzed by Western blotting for 
detection of VEGF and FGF-2 expression. (C) HFs were cultured for 24 h with 
conditioned medium (CM) from PC3 or G5-FI-RGD-rapamycin (G5-Rapa, 200 nM) 
treated PC3 and analyzed by Western blotting for detection of VEGF and FGF2. (D) 
HDMEC and human or mouse fibroblast cells (HF or MF) were treated with G5-FL-
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RGD-rapamycin (G5-Rapa, 200 nM) for 24 h and culture supernatants were assayed by 
ELISA for detection of secreted VEGF. Data represent average mean ± SD from 
duplicate assays, and the experiments were performed twice. * P < 0.001; # P < 0.002; 
n.s., not significant. 
 
Fig. 4. G5-RGD-rapamycin inhibits fibroblast mediated PCa progression in vivo. PC3 
cells treated with/without G5-FI-RGD-rapamycin (G5-R, 200 nM) for 12 h were injected 
or co-injected with either human or mouse fibroblast cells (HF or MF) treated 
with/without G5-FI-RGD-rapamycin (G5-R, 200 nM) for 12 h into the flank of SCID 
mice. (A) The volume of tumor xenografts was monitored for 22 days. Data represent 
average mean ± SE. * P < 0.005; # P < 0.05; n.s., not significant. The number of mice 
analyzed is indicated. (B) Representative micrographs of factor VIII stained tumor 
sections at 10X magnification. Scale bars, 200 µm. (C) The number of blood vessels in 
six random fields was counted per experimental condition under light microscope. Data 
represent average mean ± SD. * P < 0.001; n.s., not significant. 
 
Fig. 5. G5-RGD-rapamycin inhibits PCa metastasis in vivo. PC3luc cells were injected 
into the left cardiac ventricle of SCID mice. Experimental groups for G5-FI-RGD-
rapamycin treatment (1 mg/kg) were as follows; Con: untreated after PC3luc cell 
inoculation, Pre: 48 h before PC3luc cell inoculation, Im: at the time of PC3luc cell 
inoculation, Post: 48 h after PC3luc cell inoculation. G5-FI-RGD-rapamycin was 
intraperitoneally treated 2 times per week for four weeks in Pre, Im, and Post. At 1, 2, 3 
and 4 week time points, bioluminescence imaging was performed. Data represent average 
mean ± SD. * P < 0.01; # P < 0.02; ## P = 0.05. The number of mice analyzed is indicated.           
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